Rigel Pharmaceuticals
RIGL
149 hedge funds and large institutions have $489M invested in Rigel Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 42 increasing their positions, 51 reducing their positions, and 15 closing their positions.
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
47% more capital invested
Capital invested by funds: $334M → $489M (+$155M)
17% more call options, than puts
Call options by funds: $2.51M | Put options by funds: $2.15M
8% more funds holding
Funds holding: 138 → 149 (+11)
0.01% more ownership
Funds ownership: 8.27% → 8.28% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.74M |
| 2 |
Goldman Sachs
New York
|
+$5.71M |
| 3 |
IAM
Ion Asset Management
Herzliya,
Israel
|
+$5.3M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$1.67M |
| 5 |
JP Morgan Chase
New York
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.3M |
| 2 |
Renaissance Technologies
New York
|
-$3.74M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.15M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$2.15M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
SEI Investments
Oaks,
Pennsylvania
| – | -$148K | -6,151 | Closed |
|
|
VF
152
Virtu Financial
New York
| – | -$110K | -4,564 | Closed |
|
|
NJBEST
153
New Jersey Better Educational Savings Trust
Trenton,
New Jersey
| – | -$108K | -4,490 | Closed |
|
154
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$107K | -4,438 | Closed |
|
|
PP
155
Paloma Partners
Greenwich,
Connecticut
| – | -$56K | -2,352 | Closed |
|
|
E
156
Ergoteles
New York
| – | -$56K | -2,340 | Closed |
|
|
MAM
157
Meeder Asset Management
Dublin,
Ohio
| – | -$54K | -2,238 | Closed |
|
158
Wolverine Trading
Chicago,
Illinois
| – | -$41.1K | -1,421 | Closed |
|
|
SC
159
Sculptor Capital
New York
| – | -$25K | -1,060 | Closed |
|
160
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -93 | Closed |
|
|
ASN
161
Advisory Services Network
Atlanta,
Georgia
| – | -$579 | -20 | -61% |
|
|
CM
162
Caption Management
Oklahoma City,
Oklahoma
| – | +$579 | +20 | New |
|
RIGL Hedge Fund Activity: Q4 2020 in Review
149 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2020, worth a combined $489M — up 47% from $334M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RIGL positions and 15 closed out — a net gain of 11 holders — while 42 added to existing stakes and 51 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $6.74M. The largest seller was Wellington Management Group, cutting an estimated $7.3M.
- 149 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2020, up from 138 in Q3 2020.
- Funds reported $489M of Rigel Pharmaceuticals stock for Q4 2020, up 47% quarter-over-quarter.
- 26 funds opened new Rigel Pharmaceuticals positions in Q4 2020 and 15 closed out, a net change of +11 holders.
- The largest Rigel Pharmaceuticals buyer in Q4 2020 was Morgan Stanley, an estimated $6.74M added.
- The largest Rigel Pharmaceuticals seller in Q4 2020 was Wellington Management Group, an estimated $7.3M sold.
Based on aggregated 13F filings for Q4 2020.